Synta to Present at the Canaccord Genuity Annual Growth Conference

Company to Webcast Presentation on August 11

LEXINGTON, Mass.--(BUSINESS WIRE)-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will be presenting at the Canaccord Genuity 31st Annual Growth Conference on Thursday, August 11 at 3:00 p.m. (ET) in Boston.

A live audio webcast and replay of the presentation will be available on the "Investors" section of the Company's website, www.syntapharma.com.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.



CONTACT:

Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.